System-On-Chip Market to hit US$ 206.79 Billion by 2026: Transparency Market Research
May 08, 2018 11:03 am UTC| Business
ALBANY, New York, May 08, 2018 -- According to a new market report pertaining to the system-on-chip market, published by Transparency Market Research, the global system-on-chip market is expected to reach US$ 206.79 Bn...
JD.com Announces First Quarter 2018 Results
May 08, 2018 11:02 am UTC| Business
BEIJING, May 08, 2018 -- JD.com, Inc. (NASDAQ:JD), China’s leading technology driven e-commerce company and retail infrastructure service provider, today announced its unaudited financial results for the quarter ended...
ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018
May 08, 2018 11:01 am UTC| Business
Geneva, Switzerland and Boston, MA - May 8, 2018- ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that...
Hunt Mining Signs First Gold Concentrate Agreement With Ocean Partners USA Inc.
May 08, 2018 11:01 am UTC| Business
LIBERTY LAKE, Wash., May 08, 2018 -- Hunt Mining Corp. (the “Corporation” or “Hunt”) (TSX-V:HMX) (OTC:HMXZF) is pleased to announce it has signed an Offtake Agreement (“Agreement”) with Ocean Partners USA, Inc. (“Ocean...
Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 08, 2018 11:01 am UTC| Business
CAMBRIDGE, Mass., May 08, 2018 -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2018 and provided a corporate update. “We made important...
Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates
May 08, 2018 11:01 am UTC| Business
Continued Global Galafold® (Migalastat) Adoption and Expansion – Reaffirms FY18 Revenue Guidance of $75M-$85M at Top End of Range Significant Momentum with Pompe Clinical, Regulatory and Manufacturing Activities - GMP...
May 08, 2018 11:01 am UTC| Business
Entry into genetically engineered T-cells marks next step in Atara’s strategy to advance leadership position in off-the-shelf, allogeneic T-cell immunotherapy SOUTH SAN FRANCISCO, Calif., May 08, 2018 -- Atara...